ロード中...
Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products
A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F(2α) analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocul...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Healthcare
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4177040/ https://ncbi.nlm.nih.gov/pubmed/25213118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-014-0151-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|